Table 3 Common types of STOPPFrail-PIM at pre-admission and at discharge

A2

Any drug without clear clinical indication

413

22

94.7

 < 0.001

B1

Lipid lowering therapies

66

58

12.1

0.088

D1

Neuroleptic antipsychotics

50

32

36.0

0.001

C1

Anti-platelet for primary prevention

41

19

53.7

 < 0.001

I1

Diabetic oral agents for stringent control

27

35

-29.6

0.131

G1

Calcium supplementation

21

18

14.3

0.468

D2

Memantine without BPSD

21

16

23.8

0.025

J1

Multivitamins

17

13

23.5

0.395

E2

High-dose H2RA (full therapeutic dose with ≥ 8 weeks)

13

4

69.2

0.012

G4

Long-term oral NSAIDs (≥ 2 months)

13

2

84.6

0.001

E1

High-dose PPI (full therapeutic dose with ≥ 8 weeks)

9

11

-22.2

0.594

H2

Alpha blockers with urinary bladder catherization

5

5

0

1.000

G2

Anti-resorptive/bone anabolic drugs for osteoporosis

4

1

75.0

0.083

E3

Gastrointestinal antispasmodics

3

1

66.7

0.158

G5

Long-term oral steroids

(≥ 2 months)

3

4

-33.3

0.565

F1

Theophylline use other than asthma

2

1

50.0

0.319

J2

Nutritional supplements

2

3

-50.0

0.707

A1

Any drug that patient persistently fails to take or tolerate

1

0

100

0.319

B2

Alpha-blockers for hypertension

1

0

100

0.319

F2

Leukotriene antagonists

1

0

100

0.319

G3

SERMs for osteoporosis

1

0

100

0.319

H1

5-Alpha reductase inhibitors with urinary bladder catherization

0

0

H3

Muscarinic antagonist with urinary bladder catherization

0

0

I2

ACE-inhibitors for diabetic nephropathy

0

0

I3

Angiotensin receptor blockers for diabetic nephropathy

0

0

I4

Systemic estrogens for menopausal symptoms

0

0

J3

Prophylactic antibiotics

0

0

Total

714

245

65.7

 < 0.001